Format

Send to

Choose Destination
Arch Cardiovasc Dis. 2009 Jan;102(1):51-8. doi: 10.1016/j.acvd.2008.09.014. Epub 2008 Nov 18.

Efficacy over time of a short overall atherosclerosis management programme on the reduction of cardiovascular risk in patients after an acute coronary syndrome.

Author information

1
Centre d'exploration, de prévention et de traitement de l'athérosclérose (Cepta), hôpital cardiologique du Haut-Levêque, avenue de Magellan, 33604 Pessac cedex, France.

Abstract

INTRODUCTION:

The prognostic significance of monitoring risk factors and adjusting treatments in patients after an acute coronary syndrome (ACS) is well documented. However, studies over the last few years show that secondary prevention objectives are rarely met. Prevention programmes are effective but their benefit is only partially maintained in long-term follow-up.

AIM OF THE STUDY:

To evaluate the efficacy of a global management programme for atherosclerosis (the CEPTA programme) on the long-term monitoring of cardiovascular risk factors, on adherence to treatment, and to compare the data of clinical events post-ACS with that contained in the scientific literature.

PATIENTS AND METHODS:

Six hundred and sixty consecutive patients were hospitalised three months after the occurrence of an ACS to evaluate residual risk factors, the atherosclerosis burden, and to undergo a treatment adjustment and a therapeutic and dietary education programme. We evaluated the impact of this long-term programme on the balance of risk factors, treatment maintenance and clinical events. At the end of an average follow-up of 20 months, 96.3% of patients were on antiaggregates, 86.0% were on beta-blockers or Verapamil, 62.4% were on angiotensin-converting enzyme inhibitors or angiotensin to receptor antagonists, 88.4% were on cholesterol-lowering medication and 75.5% were receiving a combination of beta-blocker antiaggregates and cholesterol-lowering drugs. Monitoring of LDL cholesterol and blood pressure was done in over 81 and 71% of patients, respectively. At 20 months of follow-up, total mortality was 3.6% and one cardiovascular event occurred in 12% of patients. In conclusion, this short programme following ACS is beneficial for the long-term management of cardiovascular risk factors and the sustainability of drug treatments.

PMID:
19233109
DOI:
10.1016/j.acvd.2008.09.014
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center